These data suggest that pioglitazone can attenuate early inflammatory damage on the BBB elicited by peripheral inflammatory factors, not limited to TNFα, during progression of IBD, likely influencing ICAM-1 mediated effects. The gene discussed is ICAM1; the disease is inflammatory bowel disease.